https://scholars.lib.ntu.edu.tw/handle/123456789/463729
標題: | Selegiline (l-deprenyl) as a unique neuroprotective agent for chronic neurodegenerative disorders - A lesson from MAO inhibition | 作者: | RUEY-MEEI WU Murphy D.L Chiueh C.C. |
公開日期: | 2004 | 卷: | 4 | 期: | 4 | 起(迄)頁: | 255-267 | 來源出版物: | Current Medicinal Chemistry - Central Nervous System Agents | 摘要: | The purpose of this review is to describe recent advances in understanding the neuroprotective effects of selegiline (N-propanyl-l-amphetamine; l-deprenyl) and the development of a variety of novel and interesting propargyl compounds that might be potentially useful in the treatment of chronic neurodegenerative brain disorders. Selegiline is a selective, non-competitive, irreversible inhibitor of monoamine oxidase (MAO) B, and is widely used as an adjunct to L-dopa in the treatment of Parkinson's disease. Recent interest in selegiline has focused on its complex neuroprotective actions against a variety of neurotoxins, and on the pathological processes of oxidative stress and apoptosis which cause neuronal death in chronic neurodegenerative brain disorders, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis. These neuroprotective effects of selegiline are due not only to MAO-B inhibition, but also to many other effects, such as suppression of free radical formation elicited by MPP+ and glutamate, up-regulation of the antioxidative enzymes, superoxide dismutase and catalase, induction of proteins interfering with the apoptotic pathway, and expression of neurotrophic factors. Recent molecular biological evidence suggests that selegiline may also alter the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and other redox active molecules such as thioredoxin in brain neurons. These unique neuroprotective mechanisms of selegiline may provide models for the synthesis of new N- propargyl analogues with different structure-activity relationships, and for the development of therapeutic strategies designed to prevent the evolution of pathologic neurodegeneration. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/463729 | ISSN: | 1568-0150 | DOI: | 10.2174/1568015043356878 | SDG/關鍵字: | 10 (n methyl n propargylaminomethyl)dibenzo[b,f]oxepin; amine oxidase (flavin containing); catalase; free radical; glutamic acid; glyceraldehyde 3 phosphate dehydrogenase; lazabemide; levodopa; monoamine oxidase B inhibitor; n 2 heptyl n methylpropargylamine; neuroprotective agent; neurotoxin; neurotrophic factor; norselegiline; pargyline; resagiline; selegiline; superoxide dismutase; thioredoxin; unclassified drug; Alzheimer disease; amyotrophic lateral sclerosis; animal cell; apoptosis; brain nerve cell; chronic disease; degenerative disease; drug mechanism; drug selectivity; enzyme inhibition; enzyme regulation; gene expression; human; human cell; mouse; nerve cell necrosis; neuroprotection; nonhuman; oxidation reduction potential; oxidative stress; Parkinson disease; protein induction; review |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。